GlaxoSmithKline/GSK

0%
-
1D1W1MYTD1YMAX

About GlaxoSmithKline

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Ticker

GSK

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Emma Walmsley

Employees

70,212

Headquarters

Brentford, United Kingdom

GlaxoSmithKline Metrics

BasicAdvanced
£68.12B
Market cap
13.66
P/E ratio
£1.20
EPS
0.57
Beta
£0.58
Dividend rate
3.53%
Dividend yield
£68.12B
0.56747
£17.22
£13.03
9.16M
£0.58
0.885
0.624
113.921
134.997
47.73%
22.548
10.99%
8.91%
41.16%
13.91%
13.665
2.246
4.995
31.291
5.47%
3.53%
3.53%
3.42%
2.43%
7.59%
2.67%
-16.6%

What the Analysts think about GlaxoSmithKline

Analyst Ratings

Majority rating from 25 analysts.
Buy

Price Targets

Average projection from 21 analysts.
14.66% upside
High £25.50
Low £12.00
£16.44
Current price
£18.85
Average price target

GlaxoSmithKline Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
4.34% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
£8.05B
-1.17%
Net income
£350M
-76.09%
Profit margin
4.34%
-75.84%

GlaxoSmithKline Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.96%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
£0.37
£0.39
£0.50
£0.29
-
Expected
£0.33
£0.35
£0.46
£0.29
£0.37
Surprise
11.87%
10.74%
8.72%
0.96%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for GlaxoSmithKline stock?

GlaxoSmithKline (GSK) has a market cap of £68.12B as of April 16, 2024.

What is the P/E ratio for GlaxoSmithKline stock?

The price to earnings (P/E) ratio for GlaxoSmithKline (GSK) stock is 13.66 as of April 16, 2024.

Does GlaxoSmithKline stock pay dividends?

Yes, the GlaxoSmithKline (GSK) stock pays dividends to shareholders. As of April 16, 2024, the dividend rate is £0.58 and the yield is 3.53%. GlaxoSmithKline has a payout ratio of 47.73% on a trailing twelve-month basis.

When is the next GlaxoSmithKline dividend payment date?

The next GlaxoSmithKline (GSK) dividend payment date is unconfirmed.

What is the beta indicator for GlaxoSmithKline?

GlaxoSmithKline (GSK) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the GlaxoSmithKline stock price target?

The target price for GlaxoSmithKline (GSK) stock is £18.85, which is 14.66% above the current price of £16.44. This is an average based on projections from 21 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell GlaxoSmithKline stock

Buy or sell GlaxoSmithKline stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing